Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer by Schneeweiss, Andreas et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody
lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in
HER3-positive, HER2-low metastatic breast cancer
Schneeweiss, Andreas; Park-Simon, Tjoung Won; Albanell, Joan; Lassen, Ulrik; Cortés,
Javier; Dieras, Veronique; May, Marcus; Schindler, Christoph; Marmé, Frederik; Cejalvo,
Juan Miguel; Martinez-Garcia, Maria; Gonzalez, Iria; Lopez-Martin, Jose; Welt, Anja; Levy,
Christelle; Joly, Florence; Michielin, Francesca; Jacob, Wolfgang; Adessi, Céline; Moisan,
Annie; Meneses-Lorente, Georgina; Racek, Tomas; James, Ian; Ceppi, Maurizio; Hasmann,








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., ... Cervantes, A. (2018).
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the
anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Investigational New Drugs, 36(5), 848-859. https://doi.org/10.1007/s10637-018-0562-4
Download date: 03. Feb. 2020
PHASE I STUDIES
Phase Ib study evaluating safety and clinical activity of the anti-HER3
antibody lumretuzumab combined with the anti-HER2 antibody
pertuzumab and paclitaxel in HER3-positive, HER2-lowmetastatic breast
cancer
Andreas Schneeweiss1 & Tjoung-Won Park-Simon2 & Joan Albanell3 & Ulrik Lassen4 & Javier Cortés5,6 &
Veronique Dieras7 & Marcus May2 & Christoph Schindler2 & Frederik Marmé1 & Juan Miguel Cejalvo8 &
Maria Martinez-Garcia3 & Iria Gonzalez3 & Jose Lopez-Martin9 & Anja Welt10 & Christelle Levy11 & Florence Joly11 &
Francesca Michielin12 & Wolfgang Jacob13 & Céline Adessi12 & Annie Moisan12 & Georgina Meneses-Lorente14 &
Tomas Racek12 & Ian James15 & Maurizio Ceppi13 & Max Hasmann13 & Martin Weisser13 & Andrés Cervantes8
Received: 21 December 2017 /Accepted: 10 January 2018 /Published online: 19 January 2018
# The Author(s) 2018. This article is an open access publication
Summary
Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family
receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients
with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-
positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received
lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by
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420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (80 mg/m2 weekly in all cohorts).
Patients in Cohort 3 received prophylactic loperamide treatment. ResultsDiarrhea grade 3 was a dose-limiting toxicity of Cohort
1 defining the maximum tolerated dose of lumretuzumab when given in combination with pertuzumab and paclitaxel at 500 mg
every three weeks. Grade 3 diarrhea decreased from 50% (Cohort 2) to 30.8% (Cohort 3) with prophylactic loperamide
administration and omission of the pertuzumab LD, nonetheless, all patients still experienced diarrhea. In first-lineMBC patients,
the objective response rate in Cohorts 2 and 3 was 55% and 38.5%, respectively. No relationship between HER2 and HER3
expression or somatic mutations and clinical response was observed. Conclusions Combination treatment with lumretuzumab,
pertuzumab and paclitaxel was associated with a high incidence of diarrhea. Despite the efforts to alter dosing, the therapeutic
window remained too narrow to warrant further clinical development. Trial registration: on ClinicalTrials.gov with the identifier
NCT01918254 first registered on 3rd July 2013.
Keywords Human epidermal growth factor receptor 3 (HER3) . ErbB3 . Phase I . Human epidermal growth factor receptor 2
(HER2) . Heregulin (HRG) . Pertuzumab .Metastatic breast cancer . Biomarker
Background
In human epidermal growth factor receptor 2 (HER2)-overex-
pressing metastatic or advanced breast cancer (BC), defined
as: immunohistochemistry (IHC) 3+ or positive by in situ
hybridization (ISH), treatments with HER2-targeting mono-
clonal antibodies trastuzumab, pertuzumab and the antibody-
drug conjugate trastuzumab emtansine (TDM-1) have demon-
strated significantly increased response rates and prolongation
of progression-free survival (PFS) and overall survival [1–6].
However, the majority of BC tumors do not show overex-
pression of the HER2 protein or HER2 gene amplification. For
these patients, especially for those in need of systemic therapy
for metastatic breast cancer (MBC), therapeutic options are
limited. Anthracycline- or taxane-based chemotherapy is indi-
cated as initial therapy for patients with hormone receptor
(HR)-negative disease and following failure of hormonal ther-
apies in HR-positive disease [7]. Apart from anti-hormonal
agents, targeted therapies are currently not established as stan-
dard of care for these patients emphasizing the significant need
for new agents and/or novel mechanisms of action.
Upregulation of HER3 signaling provides an Bescape
route^ via which tumor cells may overcome the inhibition of
individual HER family members or downstream signaling
components of the PI3K-AKT-mTOR signaling pathway [8].
Previous reports suggested that increased HER3 expression
was associated with decreased survival of patients with BC
[9]. Our hypothesis was that in HER3-positive, HER2-low
expressing MBC, tumor growth would depend mainly on
heterodimerization of HER family receptors in contrast to
HER2-overexpressingMBCwhere HER2 signaling is the ma-
jor driver of tumor growth. In the absence of a single driver
like amplified HER2, a comprehensive inhibition of HER
family dimers may be required to inhibit tumor growth. This
could be achieved by combining the HER3-binding antibody
lumretuzumab with the HER2 dimerization inhibitor
pertuzumab, which would block all possible heterodimers
among EGFR, HER2 and HER3.
Clinically, both lumretuzumab [10] and pertuzumab [11]
given as single agents have demonstrated favorable safety
profiles but limited clinical activity in the setting of HER2-
non-overexpressing MBC. Additive tumor growth inhibition
and tumor regression was observed in subcutaneous BC xe-
nograft models expressing both HER3 and HER2 (HER2-am-
plified and non-amplified), as well as in estrogen receptor-
positive and triple-negative BC models [12, 13]. Preclinical
models demonstrated superior antitumor activity when
lumretuzumab was combined with pertuzumab as compared
to the combination with trastuzumab or TDM-1, as well as
superior antitumor activity compared to any of the mentioned
single agents (data not shown).
This phase Ib study evaluated the safety and tolerability
and clinical activity of lumretuzumab, administered in combi-
nation with pertuzumab and paclitaxel in patients with HER3-
positive, HER2-low BC. Paclitaxel 80 mg/m2 every week
(qw) was chosen as a chemotherapy backbone due to its wide-
spread use in the therapy of MBC.
Methods
Study design
This phase Ib, open-label, dose-escalating study (ClinicalTrials.
gov Identifier: NCT01918254) investigated the safety,
pharmacokinetics (PK), pharmacodynamics (PD) and clinical
activity of lumretuzumab in combination with pertuzumab and
paclitaxel. The study was conducted in two phases: a dose
escalation phase and an extension phase.
Ethics
Local ethics committee approval was obtained and all patients
provided written informed consent. The study was conducted
in accordance with Good Clinical Practice guidelines and the
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Declaration of Helsinki in nine centers in Denmark, France,
Germany and Spain.
Patients
Patients had a histologically confirmed diagnosis of MBC and
were either untreated (i.e. first line) or previously treated for
MBC. Patients eligible for enrollment underwent a fresh
(pretreatment) tumor biopsy that was used to assess the level
of HER3 protein expression by IHC and central pathology
review. HER3 expression was assessed by using a prototype
IHC assay developed by Ventana Inc. and performed by
Source Bioscience Ltd. Any discernible HER3 membrane
staining in any neoplastic cell provided a minimum of 100
tumor cells were present in the biopsy specimen was consid-
ered positive for HER3 protein expression. At the same time,
tumor biopsies had to show a low HER2 expression, i.e. IHC
1+/ISH- or IHC 2+/ISH- according to the ASCO HER2 Test
2007 Guidelines [14] and as assessed by parallel testing of
protein and gene amplification at Source BioScience Ltd.
(Nottingham, UK) using the Pathway HER2 IHC assay
(Ventana Inc., USA) and the PathVysion HER2 FISH assay
(Abbott Laboratories, USA).
Study drug administration
Lumretuzumab and pertuzumab were administered every
three weeks (q3w) and paclitaxel was administered every
week (qw) as an IV infusion defining a treatment cycle of
21 days.
As shown previously, lumretuzumab PK was linear for
doses of at least 400 mg IV, indicative of target-mediated drug
disposition (TMDD) saturation, and PD activity was demon-
strated for monotherapy when administered every two weeks
(q2w) [10]. The TMDDmodel predicted that a lumretuzumab
dose of ≥800 mg would be required to ensure adequate serum
levels and target saturation for the entire dosing period when
administered q3w [15]. Therefore, the dose of 1000 mg was
considered as the starting dose for the combination treatment
in Cohort 1. In Cohorts 2 and 3, the dose was reduced to
500 mg. For pertuzumab, the standard dose (840 mg loading
dose [LD] followed by 420mg at the following infusions) was
used in Cohorts 1 and 2. In Cohort 3, pertuzumab doses of
420 mg for the first and following infusions was administered.
Paclitaxel was given at a standard dose of 80 mg/m2 for all
cohorts. No dose reductions were allowed for pertuzumab or
lumretuzumab. In case of paclitaxel-related toxicities, the dose
of paclitaxel could be reduced once to 60 mg/m2. Paclitaxel,
pertuzumab and lumretuzumab administration could be de-
layed to assess or treat related adverse events (AEs) for up to
21 days.
Prophylactic antidiarrheal treatment with loperamide was
introduced in Cohort 3 and consisted of: 4 mg prior to Cycle 1
followed by 2 mg every 4 h on Day 1 of Cycle 1, 2 mg every
4 h from Day 2 to 4 of Cycle 1, 1 mg every 6 to 8 h between
Day 5 to 21 of Cycle 1, and titrated as needed for all subse-
quent cycles.
Patients continued treatment until disease progression, un-
acceptable toxicity or withdrawal of consent.
Tumor response and safety assessments
Tumor response assessment using Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 [16] was con-
ducted at screening and every 9 weeks thereafter.
Safety assessments included physical (ECOG performance
status, vital signs) and laboratory examinations, electrocardio-
gram and echocardiogram. AEs were defined according to the
Common Terminology Criteria for Adverse Events, version
4.03 (CTCAEv4.03).
Definition of dose-limiting toxicity (DLT)
For Cohort 1, a DLT was defined as an AE occurring during
the first cycle of treatment with lumretuzumab and considered
study drug-related. For Cohorts 2 and 3, the DLT period was
extended to two treatment cycles. AEs qualifying as DLTs
included: grade 4 neutropenia (i.e. absolute neutrophil count
[ANC] < 0.5 × 109 cells/L for minimal duration of seven
days); grade 3 and 4 febrile neutropenia; grade 4 thrombo-
cytopenia; grade 3 thrombocytopenia associated with
bleeding episodes; grade ≥ 3 non-hematological toxicity;
failure to recover from any treatment-related toxicity
grade ≥ 2 which results in a dose delay of >14 days of the
next scheduled administration; grade 3 neuropathy that
causes a dose delay of >14 days. IRRs, alopecia, grade 3
nausea and vomiting and diarrhea that respond to optimal
management, grade 3 diarrhea lasting for ≤2 days with no
fever or dehydration and laboratory values of ≥ grade 3
which were judged not clinically significant by the inves-
tigator were not considered DLTs.
Pharmacokinetic assessments
PK evaluation was conducted for all patients on Day 1 to 20 of
Cycle 1. PK parameters (area under the serum concentration–
time curve [AUC], maximum-observed serum concentration
[Cmax], half-life [t1/2], volume of distribution [Vd] and clear-
ance [CL]) for lumretuzumab and pertuzumab were computed
by non-compartmental analysis (NCA; WinNonlin Version
6.4.0, Pharsight Corp.).
Biomarker assessments
Fresh tumor biopsies were collected during screening. HER3
and HER2 protein expression was assessed using an IHC
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assay, scored semi-quantitatively and reported as an Immuno-
reactive Score (IRS, range 0 to 3) as described previously [10].
Heregulin (HRG) mRNA expression, considered a poten-
tial predictive biomarker for lumretuzumab activity, was mea-
sured by quantitative real-time PCR (qRT-PCR) assay at
Roche Molecular Systems (Pleasanton, USA) in screening
formalin-fixed, paraffin-embedded (FFPE) tumor biopsies
from a limited number of patients (n = 8).
Total RNA was isolated from FFPE tumor tissue sections
using the Cobas® RNA isolation kit. Taqman probes were
designed to detect HRG and respective reference genes simul-
taneously. All reagents were prepared at Roche Molecular
Systems and qRT-PCR was performed using the Cobas®
4800 system. Calculation of the cycle-to-threshold (Ct) for
each fluorescent channel was done using LC480 software
and the relative log HRG expression was reported as ΔCt
where ΔCt = Ct(Reference) – Ct(Target). Where feasible bi-
opsies with less than 50% tumor content underwent macro-
dissection guided by pathologist annotation of adjacent hema-
toxylin and eosin (H&E)-stained sections. No reference
ranges were defined for HRG mRNA expression using the
research grade assay.
Tumor DNA mutations were investigated in all patients
where sufficient baseline FFPE material was available using
the FoundationOne® version T7 genomic profiling assay
(Foundation Medicine Inc., Cambridge, MA, USA) [17].
Statistical considerations
All patients who received at least one dose of study medica-
tion were included in the safety and efficacy population.
Descriptive statistics were used for demographics and safety,
as well as for efficacy and biomarkers. In addition, in order to
evaluate the potential relationship of predose expression of
HER3 and HER2 with clinical response, a Fisher’s Exact
Test for assessing the association between baseline value of
the biomarker (IRS score – below or above median - or IHC
score) and the presence or absence of response was used.
Results
Patients
Patient demographics and baseline characteristics are present-
ed in Table 1. In the dose escalation phase, 2 patients were
initially treated with 1000 mg of lumretuzumab in Cohort 1.
DLTs occurred in both patients (diarrhea grade 3, hypokalemia
grade 4 and hyponatremia grade 3 in Cycle 1 in one patient;
and diarrhea grade 3 in Cycle 1 in the other patient).
Subsequently, six patients were tested at a reduced dose of
500 mg of lumretuzumab in Cohort 2, and no DLTs were
reported. Another 14 patients were enrolled into Cohort 2 as
an extension phase. Due to the unfavorable safety profile with
regard to diarrhea in Cohort 2, Cohort 3 was initiated. Based
on the PK profile of lumretuzumab, we expected that further
dose reductions would lead to the loss of linear PK and rapid
clearance of lumretuzumab. Therefore, and because of the
early onset of diarrhea, we omitted the LD of pertuzumab as
the next step of dose modification and introduced a prophy-
lactic anti-diarrheal medication for Cohort 3. No DLTs were
reported in the first 6 patients and another seven patients were
enrolled into Cohort 3.
Overall, 23 patients (65.7%) discontinued the study due to
progressive disease, eight patients (22.9%) were withdrawn
due to an AE (considered related to study treatment in 7 pa-
tients [20.0%]), two patients (5.7%) refused further treatment,
and two patients (5.7%) were withdrawn at the discretion of
the investigator.
Safety
A total of 657 AEs were reported in 35 patients (Table 2). The
most frequent AEs, irrespective of relationship to study treat-
ment, included diarrhea (35 patients [100%]), nausea (24 pa-
tients [68.6%]), hypokalemia (20 patients [57.1%]) and
weight loss (18 patients [51.4%]). The most frequent ≥ grade
3 AEs included diarrhea (16 patients [45.7%]) and hypokale-
mia (14 patients [40.0%]). AEs leading to withdrawal from the
study in 9 patients (25.7%) were: diarrhea (6 patients
[17.1%]), left ventricular dysfunction, weight loss and de-
creased appetite (1 patient [2.9%] each).
Diarrhea and hypokalemia were the most prominent
AEs in this study. Both patients of Cohort 1 (100%) had
≥ grade 3 diarrhea. In Cohort 2, 10 patients (50.0%) had
grade 1/2 diarrhea as highest grade and 10 patients (50.0%)
had ≥ grade 3 diarrhea; and 2 patients (20.0%) had grade 1/
2 hypokalemia and 11 patients (55.0%) had ≥ grade 3 hy-
pokalemia, all occurring concomitantly with an episode of
diarrhea. Reducing the dose of paclitaxel from 80 to
60 mg/m2 or interrupting the dose did not have an impact
on the course of diarrhea and hypokalemia in Cohort 2. In
Cohort 3, after implementation of loperamide prophylaxis
and omission of the LD of pertuzumab, 9 patients (69.2%)
had grade 1/2 diarrhea and 4 patients (30.8%) had ≥ grade
3 diarrhea; and 3 patients (23.1%) had grade 1/2 hypoka-
lemia and 2 patients (15.4%) had ≥ grade 3 hypokalemia.
Pharmacokinetic analysis
Lumretuzumab PK parameters at Cycle 1 are shown in
Table 3. Lumretuzumab PK parameters in Cohort 1 and 2
were in the expected range for a 500 mg dose based on the
first-in-human dose escalation study of lumretuzumab as
monotherapy [10]. Data from this previous study indicated
that lumretuzumab ≥400 mg was in the dose-linear range
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and target saturation would be ≥95% over the dosing inter-
val. The similarities in PK parameters to those following
lumretuzumab monotherapy indicate that there is no influ-
ence of pertuzumab on the PK of lumretuzumab. Only two
patients received lumretuzumab at 1000 mg (Cohort 1).
Pertuzumab PK parameters at Cycle 1 are shown in
Table 3. For pertuzumab, following administration of a LD
of 840 mg (Cohort 1 and 2), the pertuzumab PKwas similar to
that observed in patients with MBC [11]. Following adminis-
tration of pertuzumab at 420 mg for Cycle 1 (Cohort 3) the
exposure (Cmax and AUClast) was approximately 50% of the
exposure observed following a 840 mg LD (Cohorts 1 and 2),
with clearance, volume of distribution and half-life remaining
in the same range.
Biomarker analysis
All patients enrolled had tumors that were HER3-positive
based on IHC analysis at screening. Retrospective analysis
of freshly stained FFPE tumor biopsy sections indicated
that HER3 was highly expressed on the membranes of
tumor cells (median [range] IRS: 2.21 [1.04 to 3], n =
35). HER2 expression at screening was scored according
to published guidelines [18] for inclusion purposes, whilst
an IRS score was calculated for further biomarker compar-
isons. Tumors of all patients enrolled were HER2-low as
described above (HER2 IHC score [n]: 1+ [23]; 2+ [12]),
with a median (range) IRS of 0.12 (0.0001 to 1.9, n = 35).
Neither baseline HER2 nor HER3 expression was associ-
ated with clinical response (all p-values from Fisher’s ex-
act tests were non-significant: p-value for HER2 IHC score
was 1; for membranous HER2 IRS: 1; for membranous
HER3 IRS: 0.72).
HRG mRNA expression was determined in a small cohort
of patients and compared to expression in patients with squa-
mous NSCLC treated with lumretuzumab and erlotinib in a
previous study, where HRG was investigated as a potential
predictive marker of lumretuzumab activity [19]. In the pres-
ent study, HRG mRNAwas lower for MBC patients than that
observed in squamous NSCLC patients (median delta Ct
[range]): MBC -3.35 [−6.78 to −1.4], n = 8; squamous
NSCLC -0.72 [−5.12 to 1.64], n = 15). There was no apparent
relationship with clinical response.
DNA sequencing data was available from predose
FFPE tumor biopsies for 32 out of 35 patients (91.4%).
Overall, 564 short variant mutations of known, likely or
unknown function were found across 236 genes with a
median read depth of 584 (range 90 to 2672). Germline
mutations in genes directly linked to the HER pathway
were retained whilst 268 other annotated germline muta-
tions were censored in the data set leaving 296 mutations
from 196 genes across 32 patients. PIK3CA and TP53
were the most commonly observed mutated genes (13
out of 32 patients [40.6%] and 11 out of 32 patients
[34.4%], respectively) (Table 4). Common PIK3CA mu-
tations were H1047R, E542K and E545A/K, each found
in 3 different patients. There was no association of
PIK3CA mutations with response. The most commonly
mutated genes are listed in Table 4.
HER3 and HER2 mutations were found in 1 and 2 out
of 32 patients (3.1% and 6.3%, respectively). HER3
V104 M and E928G mutations were found in Patient
1374 (best RECIST response of stable disease [SD])
which were heterozygous with allele frequencies of 39%
and 29%, respectively, potentially conferring a degree of
ligand-independent activation and increased constitutive
phosphotransferase activity [20].









Age, median (range), years 52.5 (42, 63) 62.0 (35, 75) 49.0 (33, 77) 60.0 (33, 77)
Sex, n (%)
Male 0 0 1 (7.7) 1 (2.9)
Female 2 (100) 20 (100) 12 (92.3) 34 (97.1)
ECOG score, median (range) 0.5 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1)
ER-positivity of primary tumor, no. of patients (%) 1 (50.0) 16 (80.0) 12 (92.3) 29 (82.9)
ER-positivity of recurrent tumor, no. of patients (%) 1 (50.0) 11 (55.0) 9 (75.0) 21 (61.8)
Previous lines of chemotherapy for MBC, median (range) 0.5 (0, 1) 1 (0, 5) 0 0 (0, 5)
No. of cycles, median (range)
Paclitaxel 2 (2, 2) 3.5 (1, 7) 6 (1, 10) –
Pertuzumab 2 (2, 2) 5 (1, 23) 5 (1, 19) –
Lumretuzumab 2 (2, 2) 5.5 (1, 23) 7 (1, 19) –
ER estrogen receptor, MBC metastatic breast cancer, n number of patients
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Table 2 Summary of adverse events of any grade and of grade ≥ 3 adverse events irrespective of the relationship to study treatment









All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3
Diarrhea 2 (100) 2 (100) 20 (100) 10 (50.0) 13 (100) 4 (30.8) 35 (100) 16 (45.7)
Nausea 1 (50.0) 0 16 (80.0) 0 7 (53.8) 0 24 (68.6) 0
Hypokalemia 2 (100) 1 (50.0) 13 (65.0) 11 (55.0) 5 (38.5) 2 (15.4) 20 (57.1) 14 (40.0)
Weight loss 1 (50.0) 0 13 (65.0) 4 (20.0) 4 (30.8) 0 18 (51.4) 4 (11.4)
Alopecia 0 0 8 (40.0) 0 9 (69.2) 0 17 (48.6) 0
Decreased appetite 1 (50.0) 0 12 (60.0) 1 (5.0) 2 (15.4) 1 (7.7) 15 (42.9) 2 (5.7)
Rash 0 0 9 (45.0) 1 (5.0) 4 (30.8) 0 13 (37.1) 1 (2.9)
Asthenia 2 (100) 1 (50.0) 7 (35.0) 1 (5.0) 3 (23.1) 1 (7.7) 12 (34.3) 3 (8.6)
Hypomagnesemia 1 (50.0) 1 (50.0) 8 (40.0) 0 3 (23.1) 0 12 (34.3) 1 (2.9)
Vomiting 0 0 6 (30.0) 0 6 (46.2) 0 12 (34.3) 0
Urinary tract infection 0 0 6 (30.0) 0 4 (30.8) 1 (7.7) 10 (28.6) 1 (2.9)
Mucosal inflammation 1 (50.0) 0 4 (20.0) 0 5 (38.5) 0 10 (28.6) 0
Dygeusia 0 0 7 (35.0) 0 3 (23.1) 0 10 (28.6) 0
Fatigue 0 0 4 (20.0) 0 5 (38.5) 0 9 (25.7) 0
Pyrexia 1 (50.0) 0 6 (30.0) 0 2 (15.4) 0 9 (25.7) 0
Nasopharyngitis 0 0 3 (15.0) 0 6 (46.2) 0 9 (25.7) 0
ALT increased 0 0 7 (35.0) 4 (20.0) 1 (7.7) 0 8 (22.9) 4 (11.4)
Infusion-related reaction 0 0 5 (25.0) 0 3 (23.1) 0 8 (22.9) 0
Neurotoxicity 0 0 4 (20.0) 3 (15.0) 3 (23.1) 1 (7.7) 7 (20.0) 4 (11.4)
AST increased 0 0 6 (30.0) 2 (10.0) 1 (7.7) 0 7 (20.0) 2 (5.7)
Abdominal pain 1 (50.0) 0 5 (25.0) 0 1 (7.7) 0 7 (20.0) 0
Anemia 1 (50.0) 0 3 (15.0) 0 3 (23.1) 0 7 (20.0) 0
Hypophosphatemia 1 (50.0) 1 (50.0) 2 (10.0) 1 (5.0) 3 (23.1) 3 (23.1) 6 (17.1) 5 (14.3)
Epistaxis 0 0 2 (10.0) 0 4 (30.8) 0 6 (17.1) 0
Headache 0 0 3 (15.0) 0 3 (23.1) 0 6 (17.1) 0
Polyneuropathy 0 0 5 (25.0) 0 1 (7.7) 0 6 (17.1) 0
Flatulence 0 0 3 (15.0) 0 3 (23.1) 0 6 (17.1) 0
Lymphopenia 0 0 1 (5.0) 0 3 (23.1) 2 (15.4) 4 (11.4) 2 (5.7)
Constipation 0 0 2 (10.0) 1 (5.0) 3 (23.1) 0 5 (14.3) 1 (2.9)
Edema peripheral 0 0 2 (10.0) 0 3 (23.1) 0 5 (14.3) 0
Hypocalcemia 1 (50.0) 0 2 (10.0) 0 2 (15.4) 0 5 (14.3) 0
Dry mouth 0 0 4 (20.0) 0 0 0 4 (11.4) 0
Stomatitis 0 0 2 (10.0) 0 2 (15.4) 0 4 (11.4) 0
Neuropathy peripheral 0 0 2 (10.0) 0 2 (15.4) 0 4 (11.4) 0
Acne 0 0 2 (10.0) 0 2 (15.4) 0 4 (11.4) 0
Erythema 0 0 3 (15.0) 0 1 (7.7) 0 4 (11.4) 0
Onycholysis 0 0 2 (10.0) 0 2 (15.4) 0 4 (11.4) 0
Pruritus 0 0 3 (15.0) 0 1 (7.7) 0 4 (11.4) 0
Back pain 0 0 2 (10.0) 0 2 (15.4) 0 4 (11.4) 0
Pain in extremity 0 0 3 (15.0) 0 1 (7.7) 0 4 (11.4) 0
Only adverse events reported by >10% of the patients overall are shown. Adverse events are ordered by decreasing frequency for all grade events in the
overall population
N = number of patients
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Antitumor activity
Clinical activity outcomes are indicated in Table 5 and best
percentage change from baseline in sum of target lesions is
shown in Fig. 1. For the 20 patients enrolled in Cohort 2, the
objective response rate (ORR i.e. % partial response [PR] +
complete response [CR]) was 30.0%, the disease control rate
(DCR, i.e. % SD + PR + CR) was 75.0% and median PFS was
4.2months. In those patients of Cohort 2 who had not received
chemotherapy for MBC (first-line patients) (n = 9) the ORR
was 55.5%,DCRwas 77.7% andmedian PFSwas 6.2months.
In the 13 patients of Cohort 3, all of which were first-line
patients, the ORR was 38.5%, the DCR was 76.9% and the
median PFS was 8.2 months.
Discussion
In this phase Ib study the combination of lumretuzumab plus
pertuzumab added to a chemotherapy backbone of paclitaxel
was evaluated in patients with HER3-positive, HER2-low ex-
pressing MBC.
The initial overall response rate of 55.5% in patients of
Cohort 2 who had not been previously treated with chemo-
therapy for MBCwas encouraging and compared favorably to
previous reports of the ORR with single agent weekly pacli-
taxel treatment ranging from 21% to 33% [21, 22]. Based on
these data, Cohort 3 (with a reduced pertuzumab LD and
prophylactic loperamide treatment to mitigate diarrhea) was
initiated and included first-line MBC patients only to decrease
heterogeneity of the population in comparison to Cohorts 1
and 2.With an ORR of 38.5% in Cohort 3, the response rate of
first-line patients in Cohort 2 could not be confirmed. PFS was
in the expected range for paclitaxel monotherapy [22].
Previous reports have demonstrated that response to
HER3-targeting therapy may be associated with the increased
gene expression of HER2 and HER3 [23] or HRG [24].
Similarly, in HR-positive, HER2-negative MBC patients, in-
creased PFS was observed for patients with tumors expressing
higher levels of HRG mRNA when treated with a HER3-
targeting monoclonal antibody plus anti-hormonal therapy as
compared to anti-hormonal therapy alone [25]. In the present
study, however, tumor HER2 and HER3 protein expression
were not associated with clinical response. HRG mRNA ex-
pression was generally too low to enable an association to
clinical activity. Mutational analyses revealed that PI3K and
TP53 mutations were amongst the most frequently mutated
genes with a prevalence in the expected range for MBC
[26]. Again no clear association with response to therapy
could be shown. Overall our data suggest that HER2-low
Table 3 Serum PK parameters











1 N 2 2 2 2 2
Mean 448 3180 3370 253 10.1
CV% 8.52 27 4.1 44.6 40.9
2 N 19 18 18 18 18
Mean 188 1430 4040 275 11
CV% 18.6 23.3 25.7 32.3 34.5
3 N 10 8 9 9 9
Mean 161 1160 4330 295 10.9
CV% 18.8 10.8 26.7 26.6 40.7
Pertuzumab
1 N 2 1 ND ND ND
Mean 155 2160 ND ND ND
CV% 15.1 ND ND ND ND
2 N 13 7 10 10 10
Mean 256 2560 4920 229 15.6
CV% 35 34.1 36.5 35.7 33.5
3 N 10 4 10 10 10
Mean 157 1260 4440 240 13.5
CV% 12.7 27.2 31.4 33.8 27.2
Abbreviations: AUClast area under the concentration-time curve up to the last measurable concentration,
Cmax maximum-observed serum concentration, CL total clearance ND not determined, t1/2 half life, Vd volume
of distribution
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expressing tumors may not depend on either HER2/HER2,
HER2/HER3, EGFR/HER2, or EGFR/HER3 signaling di-
mers and that the escape mechanisms to lumretuzumab +
pertuzumab therapy may be multifaceted or simply undetect-
able in our cohort of MBC patients.
In this study, diarrhea accompanied by hypokalemia was
the major toxicity across all dose cohorts. In Cohort 1, two out
of two patients experienced grade 3/4 diarrhea and hypokale-
mia that were both considered dose-limiting. In a first step, the
lumretuzumab dose was reduced from 1000 mg to 500 mg and
no DLTswere reported in Cohort 2. Nevertheless, the incidence
of diarrhea and hypokalemia was high (≥ grade 3 diarrhea:
50.0%; ≥ grade 3 hypokalemia: 55.0%). As the onset of diar-
rhea was within the 1st cycle for the vast majority of patients,
we omitted the LD of pertuzumab as a next step in order to
significantly decrease the exposure in the first cycle.
Furthermore, we introduced a prophylactic loperamide treat-
ment regimen and an intensified blood electrolytes monitoring.
Overall, a reduction in the incidence of ≥ grade 3 diarrhea to
30.8% and of ≥ grade 3 hypokalemia to 15.4% in Cohort 3 was
reported. Notwithstanding that prophylactic loperamide intake
decreased the severity of diarrhea, chronic diarrhea remained
Table 4 Most prevalent gene mutations observed in predose formalin-fixed, paraffin-embedded tumor biopsies using the FoundationOne® genomic
profiling assay
Gene Prevalence (n) Total
mutations
Mutations (n)
PIK3CA 40.6% (13) 15 H1047R (4), E542K (3), E545K (3), E545A (1), E365Q (1), P124L (1), N1068 fs*3+ (1), G106-E109del (1)
TP53 34.4% (11) 11 Q52H (1), V157E (1), V173 M (1), R175M (1), L194R (1), Y220C (1), S241F (1), R248Q (1), R248W (1),
R280T (1), L194R (1)
GATA3 28.1% (9) 12 P191H (1), H237fs*29 (1), H282_Y283 >QHY (1), M357I (2), S402 fs*45+ (1), P409fs*38+ (1), S427 fs*20+
(1), T441 fs*6+ (1), M443 fs*4+ (1), A70D (1), P42L (1)
MLL3 18.8% (6) 9 R2296H (1), K2797 fs*26 (1), N2990 fs*4 (1), E4049* (1), R4595G (1), R4139* (1), E1748K (1), E1746* (1),
C438Y (1)
ESR1 18.8% (6) 7 D538G (3), S118P (1), T496 N (1), L536P (1), L549P (1)
BRCA2 15.6% (5) 6 R1190W (1), I1859fs*3 (1), R2027K (1), K2404 fs*7 (1), R2502H (1), K3326* (1)
LRP1B 15.6% (5) 5 A960V (1), E2998K (1), R2443H (1), R2777* (1), H112Y (1), S3586 T (1)
SPEN 12.5% (4) 9 R187W (1), T838R (1), I1159fs*28 (1), N2072 fs*51 (1), E2176* (1), T3104 M (1), A3169V (1), E2260K (1),
S2120F (1)
ARID1A 12.5% (4) 6 S1138 fs*55 (1), G1711A (1), V1834A (1), D1850fs*33 (1), Q2176fs*48 (1), Splice site 3406 + 1G> T (1)
JAK1 12.5% (4) 6 G319 W (1), Q834* (1), R839Q (1), K860 fs*16 (1), E1051* (1), splice site 2404-1G >A (1)
n = number of patients with mutations
Single nucleotide polymorphism gene mutations annotated as: gene, amino acid change. Tabulated mutations include those of known status (short-
variants that are recurrent somatic; copy-number alterations involving genes that are recurrently amplified/deleted; rearrangements involving known
fusion partners, or other known functional events), likely status (short-variants that disrupt tumor suppressor genes or are in known hotspot regions;
rearrangements that disrupt tumor suppressor genes or other likely functional events) and unknown status (variants with unknown somatic/functional
status). Additionally germline mutations in genes linked to the ErbB3 pathway are included in the overall analysis (n = 20 mutations). Full listing of
mutations is provided in Supplementary Table 2
Table 5 Tumor response to









Complete response 0 1 (5.0) 1 (11.1) 0
Partial response 0 5 (25.0) 4 (44.4) 5 (38.5)
Stable disease 2 (100) 9 (45.0) 2 (22.2) 5 (38.5)
Progressive disease 0 4 (20.0) 1 (11.1) 2 (15.4)
Lost to follow up 0 1 (5.0) 1 (11.1) 1 (7.7)
Objective response rate 0 6 (30.0) 5 (55.5) 5 (38.5)
Disease control rate 2 (100) 15 (75.0) 7 (77.7) 10 (76.9)
N = number of patients
Cohort 2a includes first-line patients of Cohort 2 only
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the major toxicity. Diarrhea observed in this study exceeded the
incidence of previously described reports of HER3-targeting
drugs in combination with trastuzumab [27–30], or for
pertuzumab therapy alone or in combination with trastuzumab
[5, 31–33]. Diarrhea observed in the present study was likely
due to complete inhibition of HER family dimers in the intes-
tinal epithelium. EGFR, HER2 and HER3 are expressed on
intestinal epithelial cell membranes and act in concert to nega-
tively regulate chloride secretion via the PI3K and PKC path-
ways [34, 35]. The physiological mechanisms causing diarrhea
were further investigated by a dedicated set of in vitro studies in
human colon cell lines and tissue explants using lumretuzumab
and pertuzumab. These experiments confirmed disinhibition of
chloride channel activity in colonocytes by HER signaling
Fig. 1 Best percent change from
baseline in sum of target lesions
and best confirmed response
according to RECIST. a Cohort
2 patients and b first-line patients
of Cohort 2 (left) and patients of
Cohort 3 (right). a Unconfirmed
partial response. Two patients are
not shownwhowere discontinued
prior to the first on-treatment tu-
mor assessment
856 Invest New Drugs (2018) 36:848–859
inhibition as the mechanism underlying the secretory diarrhea
reported in patients [36].
Conclusions
Despite multiple mitigation efforts by dose modifications of
study drugs and prophylactic loperamide treatment, chronic
diarrhea remained the major side effect. In addition, the prom-
ising initial antitumor activity could not be confirmed, limiting
the options to improve the therapeutic index. The therapeutic
window for the combination of lumretuzumab with
pertuzumab and paclitaxel turned out to be too narrow to
warrant further development in HER3-positive, HER2-low
MBC. The strategy to combine HER3-targeting agents with
EGFR-targeting agents has been tested in several clinical trials
over the recent years and has yet failed to provide a clinically
meaningful proof of concept [37–39]. In the light of the pres-
ent study in HER3-positive, HER2-low MBC it is debatable
whether combination of HER3-targeting agents with HER
family inhibitors, particularly in tumors lacking a single mo-
lecular driver, is worth pursuing.
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